|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression
A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
100 Clinical Results associated with Mediti Pharma, Inc.
0 Patents (Medical) associated with Mediti Pharma, Inc.
100 Deals associated with Mediti Pharma, Inc.
100 Translational Medicine associated with Mediti Pharma, Inc.